Cover Image

Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis

The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infection over time, using a large database of high-risk individuals (<i>n</i> = 5583). We use...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Garcia-Cremades (Author), Craig W. Hendrix (Author), Priya Jayachandran (Author), Natasha Strydom (Author), Leah Jarlsberg (Author), Robert Grant (Author), Connie L. Celum (Author), Michael Martin (Author), Jared M. Baeten (Author), Jeanne Marrazzo (Author), Peter Anderson (Author), Kachit Choopanya (Author), Suphak Vanichseni (Author), David V. Glidden (Author), Radojka M. Savic (Author)
Format: Book
Published: MDPI AG, 2022-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infection over time, using a large database of high-risk individuals (<i>n</i> = 5583). We used data from placebo recipients in five phase III PrEP trials: iPrEx, conducted in men who have sex with men and transgender women; VOICE, conducted in young women at high sexual risk; Partners PrEP, conducted in HIV serodiscordant heterosexual couples; TDF2, conducted in high-risk heterosexual men and women; and BTS, conducted in persons who inject drugs. The probability of HIV infection over time was estimated using NONMEM7.4. We identified predictors of HIV risk and found a substantial difference in the risk of infection among and within trial populations, with each study including a mix of low, moderate, and high-risk individuals (<i>p</i> < 0.05). Persons who were female at birth were at a higher risk of HIV infection than people who were male at birth. Final models were integrated in a tool that can assess person-specific risk and simulate cumulative HIV risk over time. These models can be used to optimize future PrEP clinical trials by identifying potential participants at highest risk.
Item Description:10.3390/pharmaceutics14091801
1999-4923

Similar Items